<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20060310123635+01'00'</creation_date><modification_date>D:20070823144253+02'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-00-168_h_dec_0.pdf</pdf_file></head><body><section><header>i</header></section><section><header>en</header><p>commission of the european communities</p><p>brussels, 23/02/2001 c(2001) 286</p></section><section><header>not for publication  
  
  
 commission decision</header><p>of 23/02/2001 granting the marketing authorization for the medicinal</p><p>
 product for human use,</p></section><section><header>&quot;tenecteplase boehringer ingelheim pharma kg - tenecteplase&quot;</header><p>only the german text is authentic.</p><p> (text with eea relevance)</p><p>ii</p></section><section><header>commission decision</header><p>of 23/02/2001 granting the marketing authorization for the medicinal</p><p>
 product for human use,</p></section><section><header>&quot;tenecteplase boehringer ingelheim pharma kg - tenecteplase&quot;</header><p>only the german text is authentic.</p><p> (text with eea relevance)</p><p>
 the commission of the european communities,</p><p>
 having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, and in particular article 10(1) and (2) thereof,</p><p> 
 having regard to the application submitted by boehringer ingelheim international 
 gmbh, on 24 september 1999, under article 4(1) of regulation (eec) no 2309/93, 
 concerning the medicinal product, &quot;tenecteplase boehringer ingelheim pharma kg - 
 tenecteplase&quot;,</p><p>
 having regard to the opinion of 18 october 2000 of the european agency for the 
 evaluation of medicinal products, formulated by the committee for proprietary 
 medicinal products,</p><p>
 whereas:</p><p>
 (1)</p><p>the medicinal product, &quot;tenecteplase boehringer ingelheim pharma kg - 
 tenecteplase&quot;, complies with the requirements of council directives 65/65/eec
 2, 75/318/eec
 3 and 75/319/eec4, as last amended by directive 93/39/eec5; (2)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use,</p><p>
 1 oj no l 214, 24. 8. 1993, p. 1. 2 oj no 22, 9.2.1965, p. 369/65. 3 oj no l 147, 9.6.1975, p. 1. 4 oj no l 147, 9.6.1975, p. 13. 5 oj no l 214, 24.8.1993, p. 22.</p><p>iiihas adopted this decision:</p><p>
 article 1</p><p>the marketing authorization referred to in article 3 of regulation (eec) no 2309/93 is hereby granted in respect of the medicinal product, &quot;tenecteplase boehringer ingelheim 
 pharma kg - tenecteplase&quot; whose characteristics are summarized in annex i hereto. this 
 medicinal product shall be entered in the community register of medicinal products 
 under the numbers:</p><p>
 eu/1/00/168/001 
 tenecteplase boehringer ingelheim pharma kg - 6,000 units (30 
 mg) - powder and solvent for solution for injection - intravenous use 
 - 1 vial + 1 pre-filled syringe</p><p>
 eu/1/00/168/002 
 tenecteplase boehringer ingelheim pharma kg - 8,000 units (40 
 mg) - powder and solvent for solution for injection - intravenous use 
 - 1 vial + 1 pre-filled syringe</p><p>
 eu/1/00/168/003 
 tenecteplase boehringer ingelheim pharma kg - 10,000 units (50 
 mg) - powder and solvent for solution for injection - intravenous use 
 - 1 vial + 1 pre-filled syringe</p><p>
 article 2</p><p>the marketing authorization concerning the medicinal product referred to in article 1 shall be subject to compliance with all the conditions, particularly those relating to 
 manufacture and/or importation, control and issue referred to in annex ii.</p><p>
 article 3</p><p>the labelling and package leaflet concerning the medicinal product referred to in article 1 shall conform to annex iii.</p><p>
 article 4</p><p>the period of validity of the authorization issued shall be five years from the date of notification of this decision. it shall be renewable under the conditions laid down in 
 article 13(1) of regulation (eec) no 2309/93.</p><p>
 article 5</p><p>this decision is addressed to boehringer ingelheim international gmbh, binger strasse 173, d-55216 ingelheim am rhein, deutschland.</p><p>
 done at brussels, 23/02/2001 
 for the commission erkki liikanen 
 member of the commision</p></section></body></xml>